Research programme: cancer therapeutics - Redx Pharma

Drug Profile

Research programme: cancer therapeutics - Redx Pharma

Alternative Names: Bruton's tyrosine kinase inhibitor - Redx Pharma; Indoleamine-2,3-dioxygenase inhibitor - Redx Pharma; porcupine inhibitor - Redx Pharma; REDX 05358; REDX 08608; RXC-004; SHP2 inhibitors - Redx Pharma; Smoothened inhibitor - Redx Pharma; T-cell target agonists - Redx Pharma

Latest Information Update: 17 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Redx Pharma
  • Developer Horizon Discovery; Redx Pharma
  • Class Small molecules
  • Mechanism of Action Protein tyrosine phosphatase non receptor type 11 antagonists; Raf kinase inhibitors; SMO protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Basal cell cancer
  • Research Colorectal cancer; Solid tumours

Most Recent Events

  • 17 Oct 2017 Early research in Solid tumours in United Kingdom before October 2017 (Redx Pharma pipeline, October 2017)
  • 02 Jun 2017 Redx Pharma plans a first-in-human phase I trial of RXC 004 for Cancer in 2017 (EudraCT2017-000720-98)
  • 02 Jun 2017 Pharmacodynamics data from a preclinical study in Cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top